MX2009006447A - Composicion farmaceutica de liberacion sostenida a largo plazo que contiene suspension acuosa de bisfosfonato. - Google Patents

Composicion farmaceutica de liberacion sostenida a largo plazo que contiene suspension acuosa de bisfosfonato.

Info

Publication number
MX2009006447A
MX2009006447A MX2009006447A MX2009006447A MX2009006447A MX 2009006447 A MX2009006447 A MX 2009006447A MX 2009006447 A MX2009006447 A MX 2009006447A MX 2009006447 A MX2009006447 A MX 2009006447A MX 2009006447 A MX2009006447 A MX 2009006447A
Authority
MX
Mexico
Prior art keywords
bisphosphonate
sustained release
aqueous suspension
pharmaceutical composition
composition containing
Prior art date
Application number
MX2009006447A
Other languages
English (en)
Spanish (es)
Inventor
Jie Fei Ding
Jack Yongfeng Zhang
Mary Ziping Luo
Dingyuan Fei
Kevin Xie
Original Assignee
Amphastar Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amphastar Pharmaceuticals Inc filed Critical Amphastar Pharmaceuticals Inc
Publication of MX2009006447A publication Critical patent/MX2009006447A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2009006447A 2006-12-21 2007-12-13 Composicion farmaceutica de liberacion sostenida a largo plazo que contiene suspension acuosa de bisfosfonato. MX2009006447A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87680006P 2006-12-21 2006-12-21
US11/768,181 US8974801B2 (en) 2006-12-21 2007-06-25 Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate
PCT/US2007/025569 WO2008085281A1 (en) 2006-12-21 2007-12-13 Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate

Publications (1)

Publication Number Publication Date
MX2009006447A true MX2009006447A (es) 2009-07-27

Family

ID=39543732

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006447A MX2009006447A (es) 2006-12-21 2007-12-13 Composicion farmaceutica de liberacion sostenida a largo plazo que contiene suspension acuosa de bisfosfonato.

Country Status (14)

Country Link
US (3) US8974801B2 (enExample)
EP (2) EP2548441B1 (enExample)
JP (1) JP5492564B2 (enExample)
CN (1) CN101616591B (enExample)
BR (1) BRPI0720605A2 (enExample)
CA (1) CA2673058C (enExample)
DK (2) DK2120585T3 (enExample)
ES (2) ES2396733T3 (enExample)
MX (1) MX2009006447A (enExample)
PL (2) PL2548441T3 (enExample)
PT (2) PT2120585E (enExample)
RU (1) RU2453316C2 (enExample)
SI (1) SI2120585T1 (enExample)
WO (1) WO2008085281A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101813728B1 (ko) * 2009-07-31 2017-12-29 그뤼넨탈 게엠베하 결정화 방법 및 생체이용률
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
AU2010330909B2 (en) 2009-12-18 2014-09-11 Howmedica Osteonics Corp. Post irradiation shelf-stable dual paste direct injectable bone cement precursor systems and methods of making same
CN102453050B (zh) * 2010-11-03 2015-01-07 成都云克药业有限责任公司 一种二膦酸化合物及其制备方法
ES2714701T3 (es) 2010-11-10 2019-05-29 Stryker European Holdings I Llc Proceso para la preparación de una espuma ósea polimérica
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
WO2013175385A1 (en) 2012-05-20 2013-11-28 Bar-Ilan Research And Development Company Ltd. Bisphosphonates vinylic monomers and polymers and uses thereof
US9492268B2 (en) 2012-11-13 2016-11-15 The Secant Group, Llc Tapered tubular implant formed from woven fabric
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
CN108815117A (zh) * 2018-08-23 2018-11-16 宁波蒙曼生物科技有限公司 一种镇痛药物组合物及其制备方法
CN109930209B (zh) * 2019-03-07 2022-02-15 华南理工大学 一种具高结晶度及长径比双膦酸盐晶体及其制备方法
CN112707934A (zh) * 2020-12-30 2021-04-27 华南理工大学 一种阿仑膦酸钙配合物及其制备方法
CN114349786B (zh) * 2021-12-28 2023-07-11 中国科学院上海硅酸盐研究所 阿仑膦酸钙超长纳米线及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356887A (en) 1990-01-31 1994-10-18 Merck & Co., Inc. Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids
US5358941A (en) 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
WO1995008304A1 (en) * 1993-09-21 1995-03-30 The Penn State Research Foundation Bone substitute composition comprising hydroxyapatite and a method of production therefor
US5462932A (en) 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
EP1028712B1 (en) 1997-09-19 2005-01-12 Shire Laboratories Inc. Solid solution beadlet
SE9703691D0 (sv) 1997-10-10 1997-10-10 Astra Ab Pharmaceutical compositions
WO1999067809A1 (en) 1998-06-24 1999-12-29 Merck & Co., Inc. Compositions and methods for inhibiting bone resorption
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
US6677320B2 (en) 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
KR100492110B1 (ko) * 2000-05-05 2005-06-02 에프. 호프만-라 로슈 아게 비스포스폰산 또는 그의 염을 포함하는 피하 투여용겔-유사 약학 조성물
US6350471B1 (en) 2000-05-31 2002-02-26 Pharma Pass Llc Tablet comprising a delayed release coating
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
JP4161031B2 (ja) 2000-10-31 2008-10-08 独立行政法人産業技術総合研究所 亜鉛含有リン酸カルシウム微粒子含有懸濁液または粒子溶媒混合系及び亜鉛欠乏症治療剤
GB0029111D0 (en) 2000-11-29 2001-01-10 Novartis Ag Organic compounds
US6558702B2 (en) 2001-04-13 2003-05-06 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
FR2836681B1 (fr) 2002-03-04 2004-06-18 Centre Nat Rech Scient Compose phosphocalcique modifie, composition injectable le contenant
US7488496B2 (en) * 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
JP2007501241A (ja) 2003-08-06 2007-01-25 ローディア インコーポレイティド 骨成長を促進する方法
US7420000B2 (en) 2003-09-10 2008-09-02 University Of Southern California Amino phosphonate and amino bis-phosphonate derivatives
US20050261250A1 (en) 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation

Also Published As

Publication number Publication date
EP2120585A4 (en) 2011-11-23
PL2120585T3 (pl) 2013-03-29
PT2120585E (pt) 2013-01-15
US20150157650A1 (en) 2015-06-11
PL2548441T3 (pl) 2015-02-27
EP2548441B1 (en) 2014-08-27
PT2548441E (pt) 2014-11-27
EP2120585A1 (en) 2009-11-25
RU2009128023A (ru) 2011-01-27
EP2120585B1 (en) 2012-10-03
CA2673058A1 (en) 2008-07-17
ES2524690T3 (es) 2014-12-11
BRPI0720605A2 (pt) 2014-04-08
US8974801B2 (en) 2015-03-10
SI2120585T1 (sl) 2013-05-31
RU2453316C2 (ru) 2012-06-20
CN101616591B (zh) 2014-06-18
CN101616591A (zh) 2009-12-30
US20080153784A1 (en) 2008-06-26
DK2548441T3 (en) 2014-12-08
JP5492564B2 (ja) 2014-05-14
US20150157649A1 (en) 2015-06-11
WO2008085281A1 (en) 2008-07-17
DK2120585T3 (da) 2013-01-21
CA2673058C (en) 2015-11-24
EP2548441A1 (en) 2013-01-23
ES2396733T3 (es) 2013-02-25
JP2010513483A (ja) 2010-04-30

Similar Documents

Publication Publication Date Title
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
BRPI0820308A8 (pt) composições farmacêuticas
BRPI0710508B8 (pt) composição de pepticorpo terapêutico liofilizado estável, kit para preparar uma composição farmacêutica aquosa, e métodos para fabricar um pepticorpo terapêutico liofilizado e para preparar uma composição de pepticorpo terapêutico reconstituído
CR20110110A (es) Composicion farmaceutica
MX2023008180A (es) Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz.
BRPI0516830A (pt) composições de droga de liberação sustentada convenientemente implantáveis
UA107112C2 (uk) Активатори розчинної гуанілатциклази
IN2012DN01216A (enExample)
IL201581A (en) Pharmaceutical formulations containing fatty acid derivatives and ion-forming substances
WO2008105773A3 (en) System for targeted delivery of therapeutic agents
UA94942C2 (ru) Фармацевтические композиции с ингибиторами dpp iv
TN2012000392A1 (en) Oral formulations and lipophilic salts of methylnaltrexone
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
BRPI0807285A2 (pt) "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto"
PT2548441E (pt) Composição farmacêutica de libertação sustentada de longa duração contendo suspensão aquosa de bisfosfonato
MX2011011829A (es) Composicion para suministro sostenido de farmaco que comprende un aglutinante geopolimerico.
UA103025C2 (ru) Твердая композиция лекарственного средства замедленного высвобождения
WO2008070141A3 (en) Compositions for delivery of therapeutic agents
MX371349B (es) Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz.
WO2010033981A3 (en) 5-azaindole bisphosphonates
ECSP066860A (es) Formulaciones de matriz oral que comprenden licarbazepina
IN2014CN02343A (enExample)
UA83900C2 (en) Amorphous forms of risedronate monosodium
UA105167C2 (uk) Кальцієва сіль периндоприлу або її сольват
AR048672A1 (es) Tabletas de desintegracion que comprenden licarbazepina

Legal Events

Date Code Title Description
FG Grant or registration